Hos cancerpatienter var den farmakokinetiske profil af Biograstim og referenceproduktet sammenlignelige efter en enkelt og gentagne subkutane doser. ###>In cancer patients, the pharmacokinetic profile of Biograstim and the reference product was comparable after single and repeated subcutaneous administration.